All In Biotech

Drug Trial Radar · NCT05233332

Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)

A Phase Ⅱ, Multicenter Open-label Study to Investigate the Efficacy and Safety of HL-085 Combined With Vemurafenib in Patients With Metastatic Colorectal Cancer (mCRC)

Last checked: Nov 20, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

186

Planned (sponsor's estimate)

Start

Feb 24, 2022

Primary completion

Jan 20, 2024

Study completion Jul 20, 2024

Sponsor

Lead sponsor
Shanghai Kechow Pharma, Inc.Industry
Sponsor type
Industry
First posted
Feb 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study consists of the two parts, phase IIa and phase IIb.

Conditions

  • CRC

Interventions

  • HL-085Drug

    12mg BID HL-085

  • VemurafenibDrug

    720mg BID Vemurafenib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR(by investigator)Time frame: up to 12 months
  2. ORR(by ICR)Time frame: up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Oncology Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.